RecruitingSolid Tumor
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors
Sponsor: Axcynsis Therapeutics Pte Ltd
You may qualify if…
- ✓ 1. At least 18 years old at the time of signing written informed consent form (ICF).
- ✓ 2. Eastern cooperative oncology group (ECOG) Performance Status score of 0 or 1 at screening and on C1D1.
- ✓ 3. Pathologically documented, definitively diagnosed, advanced/metastatic solid tumor that is resistant or refractory to standard treatment, for which no further standard treatment is available, or the subject refuses or cannot tolerate standard therapy. Subjects must have measurable lesion according to response evaluation criteria in solid tumors (RECIST) v1.1.
- ✓ 3a) Monotherapy dose escalation study (Phase 1a):
- ✓ Subjects (with documented CLDN6 expression after the lower three dose levels) will be enrolled, including but not limited to the following histological subtypes: serous or endometrioid ovarian cancer, primary peritoneal cancer or fallopian tube cancer, endometrial cancer, NSCLC, breast cancer, esophageal cancer, and gastric/GEJ cancer. There is no upper limit on the number of prior treatment regimens the subject may have received.
- ✓ 3b) Monotherapy cohort expansion study (Phase 1b)
- ✓ Subjects must meet the minimum requirement of CLDN6-expressing by IHC (cutoff value to be determined based on Phase Ia data and/or clinical studies of other CLDN6-targeting drugs), to be confirmed prior to enrollment.
- ✓ Three cohorts will be involved:
You may not qualify if…
- ✕ 1. Subjects previously received or is currently receiving any systemic anti-cancer therapy within 4 weeks or 5xT(1/2) if 5xT(1/2) of the drug/therapy used by the subject is confirmed to be \< 4 weeks, 5xT(1/2) shall prevail\] - prior to first dose of IMP
- ✕ 2. Not yet recovered to Grade 1 or baseline for treatment-related toxicities related to previous treatment with the exception of alopecia. The recovery time after surgery was less than 28 days
- ✕ 3. Subjects with clinically significant congenital or acquired cardiovascular diseases.
- ✕ 4. Presence of other active invasive cancers other than the one treated in this study within 5 years prior to screening, except appropriately treated BCC of the skin or in situ carcinoma of uterine cervix, or other local tumors considered cured by local treatment
- ✕ 5. Subjects with severe or uncontrolled systemic disease, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, or active infection requiring intravenous injection (IV) of antibiotics, antivirals or antifungals
- ✕ 6. Subjects with medical history of clinically significant lung disease or who are suspected to have these disease by imagining at screening
- ✕ 7. Live vaccine within 4 weeks prior to first dose of IMP
- ✕ 8. Presence of active or untreated metastases to central nervous system or meninges or other evidence showing that metastatic lesions in central nervous system or meninges that have not yet been controlled at screening. Note: Subjects with central nervous system or meningeal metastases who are free of neurological symptoms not managed with steroids and stable by imagining 28 days after treatment prior to the first dose may be considered for enrollment
Where it's recruiting
Source: ClinicalTrials.gov · NCT06809114 · last updated 2026-10-13